Elizabeth Holmes was once hailed as the next Steve Jobs, a brilliant Stanford dropout who founded the revolutionary blood testing startup Theranos. However, her house of cards soon came crashing down in one of the biggest fraud cases Silicon Valley has ever seen. This article will provide a comprehensive overview of the key events, factors, and lessons learned from the shocking saga of Holmes and Theranos.
The Early Promise of Elizabeth Holmes and Theranos
Elizabeth Holmes Drops Out of Stanford to Pursue Her Vision
In 2003, 19-year old Elizabeth Holmes dropped out of Stanford University to found Theranos, a biotech company focused on reinventing blood testing. Inspired after her fear of needles left her with an aversion to traditional blood tests, Holmes aimed to develop painless blood tests that required only a finger prick and a couple drops of blood. She named the company by combining “therapy” and “diagnosis”.
Theranos Promises Revolutionary Blood Testing Technology
Theranos promised it had developed revolutionary technology that could run hundreds of medical tests on just a single drop of blood pricked from a finger. Typical lab tests require a full vial of blood drawn with a needle from a vein. This new method would be faster, cheaper, and less invasive.
Holmes Assembles an All-Star Board and Advisors
To help give Theranos credibility, Holmes assembled an impressive board of directors and advisors including former Secretary of State George Shultz, former Secretary of Defense William Perry, former Wells Fargo CEO Richard Kovacevich, and former Senators Bill Frist and Sam Nunn. She was building an image of Theranos as a promising, revolutionary company.
Theranos Partners with Walgreens for Retail “Wellness Centers”
In 2013, Theranos reached a major deal with Walgreens to launch in-store blood testing “wellness centers” across the country. Customers could get test results in as little as two hours for a fraction of the typical cost without a doctor’s order. The potential disruptive impact to the $75 billion lab testing industry was massive.
Holmes Becomes Celebrity on Forbes and Fortune Cover Stories
Holmes landed magazine cover stories and was hailed as the world’s youngest female self-made billionaire. She modeled her image after Steve Jobs, sporting a signature black turtleneck and lofty visionary proclamations about changing the world. Investors were clamoring to get a piece of the hot startup.
Cracks Emerge in Theranos’ Facade
Theranos Stays Secretive While Making Grandiose Claims
While the media hype soared, Theranos remained secretive about how its technology actually worked, citing intellectual property confidentiality. But Holmes continued making bold claims about Theranos’ capabilities that sounded too good to be true to industry skeptics.
Whistleblowers Begin Raising Red Flags About Technology
Former employees and insiders started coming forward as whistleblowers raising doubts about Theranos’ technology and testing methods. They claimed the Edison device relying on just a drop of blood was inaccurate and unreliable, so the company was actually using third-party devices and diluting samples for most tests.
WSJ Exposes Major Problems with Theranos Technology
In 2015, WSJ reporter John Carreyrou published a series of damning exposés revealing major problems with Theranos’ technology and calling Holmes’ credibility into question. Theranos vigorously denied the reports, but more red flags emerged.
Holmes’ Net Worth Plummets as Problems Mount
With revelations about its defective technology, Theranos was forced to void two years of results from its tests. The company’s $9 billion valuation soon plummeted along with Holmes’ net worth. Lawsuits were filed by patients, investors, and Walgreens alleging fraud and deceit. The house of cards was crumbling.
Regulators Shut Down Theranos Labs Citing Risk to Patients
In 2016, regulators banned Holmes from owning or operating a medical lab for two years, declaring Theranos’ labs posed “immediate jeopardy to patient health and safety”. By 2018, the company announced it would shut down its labs and testing centers for good. The bold vision had ended in failure.
The Aftermath and Legacy of the Theranos Fraud Case
Holmes Faces Criminal Fraud Charges from DOJ, SEC
In 2018, Holmes was indicted on federal wire fraud charges alleging she knowingly deceived investors, doctors, and patients. That same year, the SEC charged Holmes with conducting “an elaborate, years-long fraud”. If convicted, she faces up to 20 years in prison. Her trial is set for August 2020.
Investors Lose Nearly $1 Billion on Theranos
Theranos investors, who poured in nearly $1 billion, ended up losing most of their money. Big name backers like Rupert Murdoch and Betsy DeVos were left with huge losses. Lawsuits are still ongoing to try recovering funds through settlements.
Holmes Becomes a Cautionary Tale About Silicon Valley “Unicorns”
Holmes embodied the Silicon Valley archetype of the visionary college dropout aiming to change the world. Her meteoric rise and spectacular fall has prompted deeper scrutiny of tech industry hype, valuations, and ethics. Comparing companies to Theranos has become shorthand for fraud.
Health Tech Companies Must Focus on Credibility and Transparency
The Theranos saga demonstrated the dangers of opaque tech companies overpromising and underdelivering in healthcare. Future health tech firms will need to embrace transparency, scientific rigor, and independent validation to earn trust. Otherwise they risk becoming “the next Theranos”.
Key Questions About the Theranos Fraud Case
Did Holmes Knowingly Commit Fraud or Was She Delusional?
A key question is whether Holmes was a con artist well aware her technology didn’t work and deliberately set out to deceive, or whether she convinced herself (and others) of her own overhyped vision and was simply delusional. Prosecutors will need to prove intent to defraud.
Where Did the Money Go?
Theranos raised nearly $1 billion from investors and partners. But most of that money is gone. Lawsuits are attempting to trace where the funds went and who should pay back investors and partners like Walgreens. Forensic accountants have been enlisted to follow the money trail.
Why Did Prestigious Figures Back Holmes for So Long?
Many seasoned leaders experienced with healthcare lent their reputations to endorse Theranos, including former cabinet members and Fortune 500 CEOs on the board. Did the star-power surrounding Holmes blind them to problems or silence their skepticism? Their continued allegiance remains somewhat puzzling.
What Lessons Emerge for Investors and Regulators?
The Theranos case exposed major blindspots for investors dazzled by bold claims and celebrity endorsements, taking risks based on minimal diligence. Regulators also failed to scrutinize Theranos’ practices until damage was already done. The lessons for future oversight and healthy skepticism are clear.
Subscribe to our list
Don't worry, we don't spam
Will Silicon Valley Learn From This Failure?
Elizabeth Holmes personified Silicon Valley’s “fake it till you make it” culture. Theranos was hailed as a unicorn until the façade crumbled. Have investors and innovators learned to moderate hype? Or will another Theranos emerge in the endless quest for the next big thing? Only time will tell.
Timeline of Key Events in the Rise and Fall of Theranos
| Year | Key Events |
| 2003 | 19 year-old Elizabeth Holmes drops out of Stanford to start blood testing company Theranos |
| 2004 | Theranos files first patent application for “medical device for analyte monitoring and drug delivery” |
| 2007 | Theranos develops early prototype device called Theranos 1.0 “Edison” |
| 2010 | Theranos announces commercial blood tests using tiny samples but keeps details secret |
| 2011 | Theranos raises $45 million funding at $1 billion valuation |
| 2013 | Theranos partners with Walgreens on retail “Wellness Centers”, raises $400 million |
| 2014 | Holmes lands magazine cover stories lauding Theranos success |
| 2015 | WSJ exposes major problems with Theranos technology |
| 2016 | Regulators ban Holmes from medical labs, Theranos voids two years of test results |
| 2018 | Theranos announces shutdown, Holmes indicted on fraud charges |
| 2019 | Theranos sued by Walgreens for breach of contract |
| 2020 | Holmes criminal fraud trial scheduled to begin in August |
Key Players in the Theranos Saga
- Founder and CEO of Theranos
- Dropped out of Stanford at 19 to start company in 2003
- Grew Theranos into $9B valuation before it all collapsed
- Indicted on criminal fraud charges in 2018
- President and COO of Theranos
- Holmes’ secret boyfriend for 12 years
- Also indicted on fraud charges in 2018
- Former Secretary of State (Reagan)
- Served on Theranos board, invested $120 million
- Defended Holmes until retiring from board in 2016
- Retired U.S. General, former Secretary of Defense
- Served on Theranos board after retiring from military
- WSJ investigative reporter
- Broke series of exposés revealing Theranos fraud starting in 2015
- Grandson of George Shultz
- Worked at Theranos as engineer before turning whistleblower
- Former Theranos lab worker
- Became whistleblower exposing testing problems
- Famous lawyer, represented Holmes
- Sought to silence Theranos critics and whistleblowers
- Theranos attorney who committed suicide in 2017
- His widow blames Theranos for his high stress defending the company
Direct Quotes and Testimonials About Theranos
“This is shoot-them-for-not-telling-the-truth bad behavior. Holmes and Balwani completely fabricated and lied to potential investors about Theranos’ technology.”
- Andrew Spiegel, criminal defense attorney
“In my opinion, the things that happened at the company in the last few years were extremely traumatic and still distressing for many people including me.”
- An ex-Theranos lab associate director and whistleblower
“At the age of 19, I walked away from an education at Stanford to pursue a cause I believed in. For the next fifteen years I poured my heart and soul into Theranos. Fighting for access to information about your own body seems like a basic human right.”
- Elizabeth Holmes’ written statement to the court
“This report shows that Theranos’ financial condition bears no resemblance to typical life science startups. I have never seen a high growth startup with no revenue, no cash and no available lines of credit.”
- Steve Tolle, forensic accountant hired by Theranos investors
“We understand how recent news about Theranos has caused many to feel frustrated, even offended at times. We are making this decision now based on what we believe is in the best interests of patients, our most important priority.”
- Theranos attorney and new Co-CEO David Taylor on shutting down operations
Conclusion and Lessons Learned
The story of Elizabeth Holmes and Theranos provides a sobering lesson about blindly buying into Silicon Valley hype. Under closer scrutiny, Theranos proved too good to be true. It failed because its core technology simply did not work.
The fraud cost investors nearly $1 billion and jeopardized patient health. It revealed lapses among regulators, investors, and the media failing to ask tough questions. The case highlights the need for transparency and independent validation with any breakthrough health technology. Ethics and patient safety must come first.
While Holmes intended to revolutionize blood testing, the only lasting disruption may be the heightened skepticism she incited. The next visionary founder with transformative healthcare claims will face far greater scrutiny. The Silicon Valley maxims “move fast and break things” and “fake it till you make it” will not fly in life sciences where lives are on the line. In the end, the Theranos fraud debacle may help curb some of the tech industry’s worst impulses. The lessons are as vital as ever.